The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)

C Fegan, J Bagshawe, G Salles, L Karlin, S Rule, N Shah, F Morschhauser, L Terriou, MJS Dyer, H Walter, C Hutchinson, G Cartron, J Sharpe, K Duffy, A Nishimura, S-I Abe, H Honda, T Yasuhiro, T Yoshizawa, J BirkettN Courtenay-Luck

Research output: Contribution to journalConference proceedings published in a journalpeer-review

Fingerprint

Dive into the research topics of 'The Bruton’s Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science